Jim Kastenmayer
Consigliere Generale presso ARRIVENT BIOPHARMA, INC.
Patrimonio netto: 114 778 $ in data 30/04/2024
Posizioni attive di Jim Kastenmayer
Società | Posizione | Inizio | Fine |
---|---|---|---|
ARRIVENT BIOPHARMA, INC. | Consigliere Generale | 01/09/2023 | - |
Segretario Aziendale | 01/09/2023 | - |
Storia della carriera di Jim Kastenmayer
Precedenti posizioni note di Jim Kastenmayer
Società | Posizione | Inizio | Fine |
---|---|---|---|
SPYRE THERAPEUTICS, INC. | Amministratore Delegato | 24/08/2022 | 29/11/2022 |
Consigliere Generale | 15/07/2021 | 16/05/2023 | |
Presidente | 24/08/2022 | 29/11/2022 | |
Segretario Aziendale | 29/11/2022 | 16/05/2023 | |
VIELA BIO, INC. | Consigliere Generale | 01/01/2020 | 01/03/2021 |
Segretario Aziendale | 01/01/2020 | 01/03/2021 | |
ASTRAZENECA PLC | Consigliere Generale | 01/05/2012 | 01/12/2019 |
Medimmune, Inc. | Corporate Officer/Principal | - | - |
Formazione di Jim Kastenmayer
Georgetown University Law Center | Graduate Degree |
Michigan State University | Doctorate Degree |
University of Virginia | Undergraduate Degree |
Statistiche
Distribuzione geografica
Stati Uniti | 8 |
Regno Unito | 2 |
Posizioni
General Counsel | 4 |
Corporate Secretary | 3 |
Graduate Degree | 1 |
Settori
Health Technology | 6 |
Consumer Services | 4 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 3 |
---|---|
ASTRAZENECA PLC | Health Technology |
SPYRE THERAPEUTICS, INC. | Health Technology |
ARRIVENT BIOPHARMA, INC. | Health Technology |
Aziende private | 2 |
---|---|
Viela Bio, Inc.
Viela Bio, Inc. BiotechnologyHealth Technology Viela Bio, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatment for autoimmune and inflammatory diseases. The firms product candidate includes inebilizumab, which is a humanized monoclonal antibody (mAb), designed to target CD19, a molecule expressed on the surface of a broad range of immune system B cells; VIB4920, which is a fusion protein designed to bind to CD40L on activated T cells, blocking their interaction with CD40-expressing B cells and potentially other binding partners; and VIB7734, which is a humanized mAb intended to be a novel treatment for autoimmune diseases where the pathology is driven principally by overproduction of type I interferons and other cytokines secreted by pDCs. The company was founded on December 11, 2017 and is headquartered in Gaithersburg, MD. | Health Technology |
Medimmune, Inc. | Health Technology |
- Borsa valori
- Insiders
- Jim Kastenmayer
- Esperienza